Woodline Partners’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
Other funds holding RCUS
GS
SCM
VPM
VCM
SL
Woodline Partners's RCUS Position: Q1 2026 in Review
Woodline Partners increased its Arcus Biosciences (RCUS) stake by 0.21% in Q1 2026, buying an estimated $173K and bringing the position to 3,777,798 shares worth $81.6M. The position accounts for 0.31% of the portfolio, ranked #61.
Woodline Partners first reported a position in RCUS in Q1 2020 and has held it in 19 quarters since. The position peaked at $89.8M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Woodline Partners held 3,777,798 shares of Arcus Biosciences worth $81.6M as of Q1 2026.
- Woodline Partners bought 8,010 Arcus Biosciences shares in Q1 2026, an estimated $173K.
- Arcus Biosciences made up 0.31% of Woodline Partners's portfolio in Q1 2026, its #61 holding.
- Woodline Partners first reported a position in Arcus Biosciences in Q1 2020 and has held it in 19 quarters since.
- Woodline Partners's Arcus Biosciences position peaked at $89.8M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.